Predicate |
Object |
contentType |
Journal Article|Research Support, U.S. Gov't, P.H.S.|Review |
endingPage |
54 |
issn |
0920-1211 |
issueIdentifier |
1-2 |
pageRange |
41-54 |
publicationName |
Epilepsy Research |
startingPage |
41 |
hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e423e98d115894f5b30465dcb1113e0c http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e57a2df28cd3d691c9ebea9a73b49d7b |
isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_321686f49bd547914ca540643434c305 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3fe39cf314b8b5f4604c82a0d332c472 |
bibliographicCitation |
Holmes GL. The interface of preclinical evaluation with clinical testing of antiepileptic drugs: role of pharmacogenomics and pharmacogenetics. Epilepsy Res. 2002 Jun;50(1-2):41–54. doi: 10.1016/s0920-1211(02)00067-0. PMID: 12151116. |
creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5ae10ba21caf850f9641291b0c17c13 |
date |
200206 |
identifier |
https://doi.org/10.1016/s0920-1211%2802%2900067-0 https://pubmed.ncbi.nlm.nih.gov/12151116 |
isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3587 https://portal.issn.org/resource/ISSN/0920-1211 |
language |
English |
source |
https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ |
title |
The interface of preclinical evaluation with clinical testing of antiepileptic drugs: role of pharmacogenomics and pharmacogenetics |
discusses |
http://id.nlm.nih.gov/mesh/M0001382 |
hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D010597 http://id.nlm.nih.gov/mesh/D004827Q000188 http://id.nlm.nih.gov/mesh/D004827Q000235 http://id.nlm.nih.gov/mesh/D023281 http://id.nlm.nih.gov/mesh/D000927Q000494 |
hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D011110Q000235 http://id.nlm.nih.gov/mesh/D004353 http://id.nlm.nih.gov/mesh/D000927Q000633 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000818 |
discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7617 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9191 |